Anti-SSA (Ro) and Anti-SSB (La) Antibody Tests: Key Differences
Anti-SSA/Ro and anti-SSB/La are distinct autoantibodies that target different protein components of the same ribonucleoprotein complex, with anti-SSA/Ro being more prevalent across multiple autoimmune diseases while anti-SSB/La is more specifically associated with Sjögren's syndrome.
Target Antigens and Molecular Structure
Anti-SSA/Ro antibodies recognize two separate proteins:
- 52 kDa Ro protein (with alpha and beta subtypes)
- 60 kDa Ro protein
Anti-SSB/La antibodies recognize:
- 48 kDa La protein (single protein, appearing as 42 kDa and 40 kDa peptides on immunoblotting) 1, 2, 3
These proteins associate with small cytoplasmic RNA particles (scYRNA) located primarily in the cytoplasm (70%) and nucleus (30%), and can appear on cell membranes during apoptosis 2.
Clinical Disease Associations
Anti-SSA/Ro Antibodies
Anti-SSA/Ro demonstrates broader disease associations 4, 1:
- Systemic lupus erythematosus (SLE): 30-83% prevalence
- Sjögren's syndrome: 50-60% prevalence
- Subacute cutaneous lupus erythematosus (SCLE)
- Neonatal lupus syndrome and congenital heart block: nearly 100% of affected mothers
- Primary biliary cirrhosis
- Undifferentiated connective tissue disease
Anti-SSB/La Antibodies
Anti-SSB/La shows more specific association 1, 5:
- Primarily associated with Sjögren's syndrome
- SLE: 41% prevalence
- When present in SLE, correlates with: low oral ulcer prevalence, low anti-dsDNA titers, presence of rheumatoid factor, and presence of anti-Sm antibodies 3
Critical clinical point: Anti-SSB/La antibodies are rarely found without concurrent anti-SSA/Ro antibodies, whereas anti-SSA/Ro frequently occurs alone 1.
Detection Methods and Performance
The international guidelines emphasize that different assay methods show variable performance for these antibodies 4:
For Anti-SSA/Ro Detection:
- Counterimmunoelectrophoresis (CIE): Most reliable for routine practice with 89% sensitivity and 100% specificity 1, 5
- RNA precipitation assay: Highest sensitivity and specificity (reference standard) 1, 5
- ELISA: 96% sensitivity but lower clinical specificity 5
- Immunoblotting: 80% sensitivity (66% when considering only 60 kDa reactivity) 5
For Anti-SSB/La Detection:
- Immunoblotting: 86% sensitivity, most closely corresponds to RNA precipitation 5
- ELISA: 98% sensitivity but only 14% specificity (high false-positive rate) 5
- CIE: Only 67% sensitivity 5
Important caveat: The differences in Ro52 kDa versus Ro60 kDa detection explain why different assays show non-equivalent performance 1. This is why the laboratory must specify which method was used 4.
Clinical Significance of Antibody Profiles
Pregnancy and Neonatal Outcomes
Anti-SSA/Ro (particularly anti-Ro52 beta) is the primary culprit in congenital heart block and neonatal lupus, with anti-SSB/La playing an associated but secondary role 2. IgG anti-Ro52 beta can directly interrupt atrioventricular conduction and L-type calcium channels in fetal cardiocytes 2.
Both antibodies are associated with:
- Lower IVF success rates
- Reduced implantation rates
- Lower take-home baby rates
- Reduced birth weight 6
Disease Phenotypes
The specific antibody profile correlates with distinct clinical phenotypes 7:
- Ro52 alone versus Ro60 alone versus combined positivity predict different disease courses
- Ro52 positivity in SLE correlates with low facial rash prevalence, anti-dsDNA presence, and low CH50 3
Testing Recommendations
When to test for specific antibodies regardless of ANA results 4:
- Anti-SSA/Ro: Suspected Sjögren's syndrome, subacute cutaneous lupus, congenital heart block risk assessment, neonatal lupus evaluation
- Anti-SSB/La: Suspected Sjögren's syndrome
Critical guideline: In cases of high clinical suspicion, request determination of anti-SSA/Ro antibodies even if ANA is negative, as these antibodies can be present in ANA-negative patients 4.
Pattern Recognition
On immunofluorescence, both antibodies typically produce a fine speckled nuclear pattern, though they are part of the broader extractable nuclear antigen (ENA) group 4.
Practical Testing Algorithm
- Screen with ANA-IIFA on HEp-2 cells as first-line 4
- If positive ANA with fine speckled pattern → reflex to specific anti-SSA and anti-SSB testing 4
- If high clinical suspicion (Sjögren's, SCLE, pregnancy planning in autoimmune disease) → test anti-SSA/anti-SSB regardless of ANA result 4
- Report results separately for anti-SSA and anti-SSB, specifying the method used 4
- For pregnancy risk assessment: Focus on anti-SSA/Ro52 titers >240 units/mL as highest risk for congenital heart block 8
The prevalence of these antibodies in RA patients wishing to conceive is low (3.9% for anti-SSA, 1.1% for anti-SSB), with higher rates in RF-positive patients 8.